Moderna/$MRNA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Ticker

$MRNA
Primary listing

Industry

Biotechnology

Employees

5,800

ISIN

US60770K1079

Moderna Metrics

BasicAdvanced
$13B
-
-$8.73
1.85
-

What the Analysts think about Moderna

Analyst ratings (Buy, Hold, Sell) for Moderna stock.

Bulls say / Bears say

Moderna's mRNA-4157, in combination with Merck's Keytruda, has shown promising results in early-stage trials for melanoma and head and neck squamous cell carcinoma, advancing to Phase III trials with potential accelerated approval pathways. (Investing.com)
The company has announced plans to cut costs by $1.4-1.7 billion by 2027, aiming to reach breakeven by 2028, demonstrating a commitment to improving its financial position. (Investing.com)
Moderna's acquisition of Japanese biotech OriCiro Genomics for $85 million is expected to enhance its mRNA synthesis process, reducing the time from design to product readiness. (Fintech Insight)
Moderna reported a larger-than-expected quarterly loss of $2.91 per share, attributed to a $238 million non-cash charge from terminating an agreement with a contract manufacturer. (Reuters)
The company faces intensifying competition in the RSV vaccine market from established players like GlaxoSmithKline and Pfizer, who have existing contracts and the ability to bundle RSV vaccines with other products. (Investing.com)
Moderna's path to profitability has been extended, with breakeven now projected for 2028, reflecting ongoing investments in research and development. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Moderna Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Moderna Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRNA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs